CN1255182C - 胸腺肽输液及其制备工艺 - Google Patents
胸腺肽输液及其制备工艺 Download PDFInfo
- Publication number
- CN1255182C CN1255182C CN 200410013642 CN200410013642A CN1255182C CN 1255182 C CN1255182 C CN 1255182C CN 200410013642 CN200410013642 CN 200410013642 CN 200410013642 A CN200410013642 A CN 200410013642A CN 1255182 C CN1255182 C CN 1255182C
- Authority
- CN
- China
- Prior art keywords
- osmotic pressure
- solution
- pressure regulator
- thymosin
- thymus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000002992 thymic effect Effects 0.000 title claims abstract description 17
- 238000001802 infusion Methods 0.000 title abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 61
- 230000003204 osmotic effect Effects 0.000 claims abstract description 45
- 210000001541 thymus gland Anatomy 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 25
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 102000007501 Thymosin Human genes 0.000 claims description 21
- 108010046075 Thymosin Proteins 0.000 claims description 21
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 11
- 230000008014 freezing Effects 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000004925 denaturation Methods 0.000 claims description 5
- 230000036425 denaturation Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 5
- 201000001322 T cell deficiency Diseases 0.000 abstract 1
- 238000011360 adjunctive therapy Methods 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 239000012085 test solution Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410013642 CN1255182C (zh) | 2004-03-25 | 2004-03-25 | 胸腺肽输液及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410013642 CN1255182C (zh) | 2004-03-25 | 2004-03-25 | 胸腺肽输液及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1579537A CN1579537A (zh) | 2005-02-16 |
CN1255182C true CN1255182C (zh) | 2006-05-10 |
Family
ID=34581690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410013642 Expired - Lifetime CN1255182C (zh) | 2004-03-25 | 2004-03-25 | 胸腺肽输液及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1255182C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934068A (zh) * | 2010-09-26 | 2011-01-05 | 武汉华龙生物制药有限公司 | 胸腺肽注射液的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1840177B (zh) * | 2006-01-11 | 2011-04-06 | 成都圣诺科技发展有限公司 | 胸腺肽α1注射液及其制备方法 |
-
2004
- 2004-03-25 CN CN 200410013642 patent/CN1255182C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934068A (zh) * | 2010-09-26 | 2011-01-05 | 武汉华龙生物制药有限公司 | 胸腺肽注射液的制备方法 |
CN101934068B (zh) * | 2010-09-26 | 2012-07-25 | 武汉华龙生物制药有限公司 | 胸腺肽注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1579537A (zh) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102256613B (zh) | 用于治疗或者预防粘连的多肽 | |
JPH033495B2 (zh) | ||
US5080796A (en) | Thermofiltration of plasma | |
CN101628025B (zh) | 包含鹿骨提取物和甜瓜籽提取物的药物组合物 | |
CN101332211A (zh) | 一种水蛭提取物及其制备方法与应用 | |
CN1255182C (zh) | 胸腺肽输液及其制备工艺 | |
CN102091043B (zh) | 一种生长因子缓释微球及其制备方法 | |
DE69722422T2 (de) | Verfahren und vorrichtung zur herstellung eines zellfreien ersatzes roter blutzellen | |
CN101402681B (zh) | 一种源自鹿花盘的多肽、其制法及其防治糖尿病的用途 | |
CN101054414B (zh) | 鹿茸表皮生长因子(deer egf)提取及其制备方法 | |
EP1419171A4 (en) | PURIFICATION OF A POLY THYL NE-GLYCOL ACTIV E SOLUTION AND SYNTH SE OF A MODIFIED H MOGLOBIN SOLUTION | |
CN1634119A (zh) | 颅内动脉瘤液体栓塞剂及其制备方法 | |
CN1192782C (zh) | 治疗心脑血管疾病的注射剂的制造方法及其产品 | |
CN105687293A (zh) | 一种鹿瓜多肽注射剂的制备方法 | |
CN110193024A (zh) | 具有高活化细胞因子的血清的制备方法 | |
CN1218747C (zh) | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 | |
KR20140091435A (ko) | 고농도 콜라겐 제조방법 | |
CN100377741C (zh) | 注射用复方骨肽及其制备工艺 | |
CN112957470A (zh) | 一种治疗结肠癌的复合物及其应用 | |
Alula et al. | Preparation characterization and blood compatibility studies of silk fibroin/gelatin/curcumin injectable hydrogels | |
CN100386113C (zh) | 脑蛋白水解物注射剂及其制备工艺 | |
Yogev | A humoral solution: Autologous blood products and tissue repair | |
CN1557465A (zh) | 脾氨肽制剂及制备工艺 | |
RU2341286C1 (ru) | Способ получения кровезаменителя и установка для осуществления способа | |
CN104356219B (zh) | 一种印鼠客蚤抗心律失常的多肽及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Heilongjiang Jiang Shi Pharmaceutical Co.,Ltd. Assignor: Jiang Weishi Contract fulfillment period: 2008.8.18 to 2008.8.18 Contract record no.: 2008230000026 Denomination of invention: Thymic peptide infusion and preparation process Granted publication date: 20060510 License type: Exclusive license Record date: 20081009 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.8.18 TO 2008.8.18; CHANGE OF CONTRACT Name of requester: HEILONGJIANG JIANGSHI PHARMACEUTICAL CO., LTD. Effective date: 20081009 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060510 |